Sampre Nutritions Limited has closed its trading window for dealing in its securities effective from July 1, 2026, to prevent insider trading ahead of its financial results. The window will remain shut until 48 hours after the declaration of the unaudited standalone and consolidated financial results for the first quarter of the financial year 2026-27 ending on June 30, 2026. The restriction applies to all promoters, directors, designated persons, specific connected persons, and their immediate relatives, who are advised not to trade in the company's securities during this closure period.

The decision is in accordance with Regulation 9 of the SEBI (Prohibition of Insider Trading) Regulations, 2015, and a specific SEBI circular dated July 19, 2023. Additionally, the closure follows the company's internal Code of Conduct designed to regulate, monitor, and report trading by designated persons. The company stated that the specific date for the Board of Directors meeting to declare the results for the quarter ending June 30, 2026, will be communicated in due course.

Key Details of the Closure

The intimation was submitted to BSE Limited on June 20, 2026, by Brahma Gurbani, Managing Director of Sampre Nutritions Limited.

Sampre Nutritions Limited returned to profitability in the financial year ended 31 March 2026, reporting a net profit of ₹386.55 lakh compared to a net loss of ₹730.92 lakh in the previous year. The turnaround was driven by a significant increase in total revenue, which rose to ₹4,405.76 lakh from ₹2,549.87 lakh in FY25. For the quarter ended 31 March 2026 (Q4FY26), the company posted a net profit of ₹182.23 lakh, reversing the net loss of ₹714.29 lakh recorded in the corresponding quarter of the previous year.

The Board of Directors approved the standalone and consolidated audited financial results for the quarter and year ended 31 March 2026 at a meeting held on 29 May 2026. The statutory auditors, N G Rao & Associates, issued an audit report with an unmodified opinion on the financial results. The meeting was conducted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance

The company's operational efficiency improved as total expenses for FY26 increased to ₹4,149.23 lakh from ₹3,266.05 lakh in the prior year, a rise that was outpaced by the revenue growth. Profit before tax for the full year stood at ₹256.53 lakh, a turnaround from the loss before tax of ₹716.18 lakh in FY25. For Q4FY26, profit before tax was ₹52.21 lakh compared to a loss before tax of ₹699.55 lakh in the same period last year.

Consolidated Results

On a consolidated basis, the company reported a net profit of ₹307.67 lakh for FY26, compared to a net loss of ₹767.23 lakh in the previous year. Total consolidated revenue for the year increased to ₹4,377.92 lakh from ₹2,549.87 lakh in FY25. For the quarter ended 31 March 2026, the consolidated net profit was ₹134.59 lakh. The financial results include the performance of subsidiaries Sampre Nutritions Holding Limited and Sampre Nutritions-FZCO.